NOSSAMAN LLP for AMERISOURCEBERGEN CORPORATION (FORMERLY "AMERISOURCEBERGEN SPECIALTY GROUP")
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Repeal of LIFO (Last in, First Out).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| SHERRY HARPER WIDICUS | — |
Medicare/Medicaid MMM
(H.R.800/S. 806) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. ASP Generally (in the context of deficit reduction). Sequestation cuts to cancer care.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| SHERRY HARPER WIDICUS | — |
Pharmacy PHA
(H.R.800/S806) Medicare Prompt Pay Discount Exclusion legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. (H.R. 1919/HR 191/HR 3204; S.957/S 959) Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting Pharmaceutical compounding.Legislation pertaining to drug manufacturing shortages. Cancer Patien Protection Act of 2013 (HR 1416)
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHELBY LYNNE HAGENAUER | — |
| BRENT HEBERLEE | — |
| TIMOTHY W JENKINS | — |
| SHERRY HARPER WIDICUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.